Published on : 10 Dec 2025, 7:31 am 2 min read

The Delhi High Court on Wednesday recorded an undertaking from Sun Pharma that it will not sell its semaglutide formulation — the drug globally sold by Novo Nordisk as Ozempic — in India until Novo Nordisk’s patent expires [ Novo Nordisk Vs Sun Pharma].

Based on the above, the Court allowed Sun Pharma to manufacture and export the drug to jurisdictions where no competing patent exists.

Semaglutide, central to Novo Nordisk’s blockbusters Ozempic and Wegovy, is at the centre of heated patent enforcement globally amid soaring demand for diabetes and weight-loss indications.

The suit by Novo Nordisk alleged infringement of its semaglutide patent. When Sun Pharma sought to rely on a December 2 ruling in an earlier case involving

See Full Page